

**Table 3.1:** Cytotoxicity activity of bis(triphenylphosphino)silver(I) and –copper(I) dithiocarbamate against human carcinoma cells models at 24 hours treatment.

Cell line	IC <sub>50</sub> (μM)								
	Cisplatin	Doxorubicin	Paclitaxel	(o)	(p)	(q)	(l)	(m)	(n)
<b>HepG2</b>	*152 ± 2.3	*4.6 ± 0.2	>80	*11.7±0.8	*11.5±0.6	*8.85±0.5	*2.8 ±0.3	*1.0 ±0.	*8.0±0.5
<b>MCF-7R</b>	*19.6 ± 0.7	*5.2 ± 0.4	*15.9 ± 1.3	*16.6 ± 0.6	*14.9 ± 0.6	*13.6 ± 0.4	*2.3 ± 0.2	*7.8 ± 0.3	*12.7 ± 0.6
<b>A2780</b>	*28.8 ± 0.7	*4.4 ± 0.2	*14.2 ± 1.1	*2.48 ± 0.4	*0.71 ± 0.03	*3.7 ± 0.5	*0.54 ± 0.04	*0.81 ± 0.03	*2.4 ± 0.3
<b>HT-29</b>	*25 ± 0.8	*4.8 ± 0.3	>80	*23.5 ± 0.7	*31.3 ± 1.3	*38.6 ± 1.6	*2.7 ± 0.4	*1.5 ± 0.2	*21.8 ± 0.9
<b>A549</b>	*35.4 ± 1.4	>80	>80	*4.25 ± 0.6	*8.32 ± 0.7	*9.03 ± 0.8	*7.4 ± 0.7	>80	*13.5 ± 0.8
<b>8505C</b>	*120 ± 1.8	>80	>80	*22.8 ± 0.9	*15.2 ± 0.9	*17.5 ± 0.4	*3.4 ± 0.6	*39.3 ± 1.3	*25.8 ± 1.0

HepG2: Human liver hepatocellular carcinoma cells

MCF-7R: Human breast carcinoma cells (multidrug resistant strain)

A2780: Human ovarian carcinoma cells

HT-29: Human colon adenocarcinoma cells

A549: Human lung adenocarcinoma epithelial cells

8505C: Human thyroid carcinoma cells

(\*  $p = 0.005$  value)